Literature DB >> 8855148

Coated-tube radioimmunoassay for C-telopeptides of type I collagen to assess bone resorption.

M Bonde1, C Fledelius, P Qvist, C Christiansen.   

Abstract

We present a coated-tube RIA that is useful for assessment of bone resorption. The assay uses a monoclonal antibody raised against a linear 8-amino-acid sequence (EKAHDGGR) derived from the C-telopeptides of type I collagen. Within-run and total CVs were 4.4% and 5.3-6.2%, respectively, at concentrations of 1-7 mg/L (n = 4-20). Analytical recovery was 98% +/- 8% and dilution 97% +/- 7%. Values obtained in a group of 36 premenopausal women were 227 +/- 89.6 mg/mol creatinine. In a group of 141 postmenopausal women, the values obtained were 429 +/- 225 mg/mol creatinine, a highly significant increase of 89% (P <0.001) over the premenopausal value. In a double-blind placebo-controlled clinical study of these postmenopausal women receiving five different doses of a bisphosphonate, a significant decrease of RIA-measured C-telopeptide values was seen in all bisphosphonate-treated groups, after just 3 months. Values in urine samples from postmenopausal women assayed with the RIA (gamma) and the CrossLaps(TM) ELISA (x) agreed well: slope = 0.98 (95% confidence interval, 0.94-1.01), intercept = 0.34 (0.25-0.43) mg/L, and Sylx = 0.93 mg/L (n = 678). We conclude that this RIA represents a valuable tool for assessing bone resorption.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8855148

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  9 in total

1.  Collagen fragments in urine derived from bone resorption are highly racemized and isomerized: a biological clock of protein aging with clinical potential.

Authors:  P A Cloos; C Fledelius
Journal:  Biochem J       Date:  2000-02-01       Impact factor: 3.857

2.  Biochemical markers of bone turnover: part I: biochemistry and variability.

Authors:  Markus J Seibel
Journal:  Clin Biochem Rev       Date:  2005-11

3.  DNA aptamer beacon assay for C-telopeptide and handheld fluorometer to monitor bone resorption.

Authors:  John Gordon Bruno; Maria P Carrillo; Taylor Phillips; Douglas Hanson; Jonathan A Bohmann
Journal:  J Fluoresc       Date:  2011-06-04       Impact factor: 2.217

4.  Biochemical markers of bone turnover may predict progression to osteoporosis in osteopenic women: the JPOS Cohort Study.

Authors:  Masayuki Iki; Akemi Morita; Yukihiro Ikeda; Yuho Sato; Takashi Akiba; Toshio Matsumoto; Harumi Nishino; Sadanobu Kagamimori; Yoshiko Kagawa; Hideo Yoneshima
Journal:  J Bone Miner Metab       Date:  2007-02-26       Impact factor: 2.626

5.  Salivary bone turnover markers in healthy pre- and postmenopausal women: daily and seasonal rhythm.

Authors:  Gretel G Pellegrini; Macarena M S Gonzales Chaves; Maria A Fajardo; Graciela M Ponce; Gloria I Toyos; Fima Lifshitz; Silvia M Friedman; Susana N Zeni
Journal:  Clin Oral Investig       Date:  2011-03-24       Impact factor: 3.573

Review 6.  Evolving role of bone biomarkers in castration-resistant prostate cancer.

Authors:  Janet E Brown; Sheryl Sim
Journal:  Neoplasia       Date:  2010-09       Impact factor: 5.715

7.  Reference database of biochemical markers of bone turnover for the Japanese female population. Japanese Population-based Osteoporosis (JPOS) Study.

Authors:  Masayuki Iki; Takashi Akiba; Toshio Matsumoto; Harumi Nishino; Sadanobu Kagamimori; Yoshiko Kagawa; Hideo Yoneshima
Journal:  Osteoporos Int       Date:  2004-07-31       Impact factor: 4.507

8.  Markers of bone turnover for the management of patients with bone metastases from prostate cancer.

Authors:  P Garnero; N Buchs; J Zekri; R Rizzoli; R E Coleman; P D Delmas
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

9.  Breast cancer patients with bone metastases are characterised by increased levels of nonisomerised type I collagen fragments.

Authors:  Paul Andreas Compare Cloos; Stephan Christgau; Nina Lyubimova; Jean-Jacques Body; Per Qvist; Claus Christiansen
Journal:  Breast Cancer Res       Date:  2003-05-19       Impact factor: 6.466

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.